Cholangitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Cholangitis – Drugs In Development, 2024 report and make more profitable business decisions.
Cholangitis refers to inflammation of the bile ducts, which are tubes that carry bile from the liver to the gallbladder and small intestine. This condition can be acute or chronic and is often caused by a bacterial infection or blockage of the bile ducts.
Cholangitis can cause a range of symptoms, which may include abdominal pain, particularly in the upper right side; jaundice (yellowing of the skin and eyes); fever and chills; nausea, vomiting, and loss of appetite; dark urine and pale stools; and generalized weakness or fatigue.
The Cholangitis drugs in development market research report provide comprehensive information on the therapeutics under development for Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cholangitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Cholangitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 45 molecules, with 43 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Cholangitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Cholangitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Cholangitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAlfasigma SpA
Avolynt Inc
Cascade Pharmaceuticals Inc
Catholic University of Daegu
Centre for Drug Design and Discovery
Chemomab Therapeutics Ltd
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Emergent Biotechnologies LLC
Engitix Ltd
Galmed Pharmaceuticals Ltd
GRI Bio Inc
Halo Biosciences Inc
Hanmi Pharmaceuticals Co Ltd
HighTide Therapeutics Inc
Hunan Sanqing Pharmaceutical Co Ltd
Iltoo Pharma
Invea Therapeutics Inc
Ipsen SA
LISCure Biosciences Co Ltd
Mirum Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Orbsen Therapeutics Ltd
Parvus Therapeutics Inc
Pliant Therapeutics Inc
ProQR Therapeutics NV
Qing Bile Therapeutics Inc
Scohia Pharma Inc
Shanghai Henlius Biotech Inc
Sirnaomics Ltd
SteroTherapeutics LLC
Takeda Pharmaceutical Co Ltd
Topas Therapeutics GmbH
Yungjin Pharm Co Ltd
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Cholangitis reports